OmniAbOABI +1.47%71 Days Payable is 10,740.13 as of Mar. 2026, which is 327% above its 10-year median of 2,515.25. GuruFocus rates OABI with a GF Score™ of 71/100 and a GF Value™ of $2.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, OmniAb ranks better than 91.03% on this metric.
OmniAb's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.77 Mil. OmniAb's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.01 Mil.
Hence, OmniAb's Days Payable for the
three
months ended in Mar. 2026 was 10,740.13.
The historical rank and industry rank for OmniAb's Days Payable or its related term are showing as below:
OABI'
s Days Payable Range Over the Past 10 Years
Min: 2166.59 Med: 2515.25 Max: 2515.25
Current: 2166.59
During the past 7 years, OmniAb's highest Days Payable was 2515.25. The lowest was 2166.59. And the median was 2515.25.
OABI's Days Payable is ranked better than 91.03% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs OABI: 2166.59
OmniAb's Days Payable
declined
from Mar. 2025 (64,331.25) to Mar. 2026 (10,740.13).
It may suggest that OmniAbaccelerated paying its suppliers.
OmniAb Days Payable Related Terms
OmniAb Days Payable Historical Data
* Premium members only.
The historical data trend for OmniAb's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OmniAb's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OmniAb Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OmniAb's Days Payable distribution charts can be found below:
* The bar in red indicates where OmniAb's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
OmniAb's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OmniAb (OABI) has a Days Payable of 10,740.13 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OmniAb and its competitors. This is 327% above median its historical median of 2,515.25. Over the past decade, OmniAb's Days Payable has ranged from 2,166.59 to 2,515.25. According to the industry distribution chart, OmniAb ranks #63 out of 702 companies in the Biotechnology industry, placing it in the top 9%.
Is OmniAb's Days Payable too high?
OmniAb's current Days Payable of 10,740.13 is 327% above median its 10-year median of 2,515.25. Over the past 10 years, this metric has ranged from a low of 2,166.59 to a high of 2,515.25. The Biotechnology industry median Days Payable is 113.56. OmniAb's value of 10,740.13 is 9357.7% above this industry median. Based on the distribution chart, OmniAb ranks #63 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OmniAb has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OmniAb's Days Payable compare to VNDA and AVIR?
According to the Biotechnology industry distribution chart, OmniAb ranks #63 out of 702 companies for Days Payable. This places OmniAb in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. OmniAb's value of 10,740.13 is 9357.7% above this benchmark. Historically, OmniAb's own Days Payable has ranged from 2,166.59 to 2,515.25 over the past decade. While the company's 10-year median is 2,515.25 vs. the industry median of 113.56, OmniAb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OmniAb's current Days Payable of 10,740.13 is 9357.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on OmniAb and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OmniAb's current Days Payable is 10,740.13, which is 327% above median its own 10-year median of 2,515.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OmniAb stock overvalued right now?
Based on GuruFocus' analysis, OmniAb (OABI) is currently considered Fairly Valued. The stock's GF Value™ is $2.27, compared to a current price of $2.42 — trading 6.6% above its estimated fair value. The current Days Payable is 10,740.13, which is 327% above median its 10-year median of 2,515.25 and 9357.7% above the Biotechnology industry median of 113.56. OmniAb's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For OmniAb (OABI), the current Days Payable is 10,740.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OmniAb (OABI) Overvalued in 2026?
Based on GuruFocus' analysis, OmniAb stock appears to be overvalued.
The current stock price of $2.42 is trading 6.6% above its estimated GF Value™ of $2.27.
GuruFocus considers OmniAb to be Fairly Valued.
Key valuation signals for OABI:
Days Payable: 10,740.13 (327% above median its 10-year median of 2,515.25)
GF Value™: $2.27 vs. price of $2.42 (6.6% above fair value)
Industry Position: 9357.7% above the Biotechnology median (#63 of 702)
No single metric tells the full story. See the OABI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
71GF Score
Get the complete analysis for OABI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OABI has been successfully added to your 
